DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Lanreotide
OtherFDA approvedRx required

Lanreotide

Also known as: Somatuline Depot · Somatuline Autogel
Brands: Somatuline Depot

Long-acting somatostatin analog approved for acromegaly and GEP-NETs.

A
Grade A
Multiple human RCTs
Human studies27
PubMed citations28
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Cyclic octapeptide somatostatin analog with SSTR2/SSTR5 activity. Supersaturated aqueous formulation provides sustained release over ~4 weeks.

Evidence summary

27
Human studies
28
PubMed citations
25
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

From the FDA label
Source
abdominal painarthralgiaback painconstipationdiarrheadizzinessheadachehypoglycemiainjection site paininjection site pruritusinjection site reactionnauseapancreatitispruritusrashvomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors (Somatuline Depot)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07534371Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort StudyActive Not Recruiting · Neuroendocrine Tumors · n=500NCT05048901A Phase I/II Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)Recruiting · Phase 1 · Neuroendocrine Tumors,Gastroenteropancreatic · n=49NCT02127437Lanreotide In Polycystic Kidney Disease StudyCompleted · Phase 3 · Autosomal Dominant Polycystic Kidney Disease (ADPKD · n=159NCT06807437A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic FistulaRecruiting · Phase 3 · Pancreatic Carcinoma · n=274NCT05477576Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyRecruiting · Phase 3 · GEP-NET · n=338NCT05361668A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid SyndromeCompleted · Phase 2 · Carcinoid Syndrome · n=36NCT07087054A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine TumorsRecruiting · Phase 3 · Carcinoid Syndrome · n=141NCT03946527Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA)Active Not Recruiting · Phase 2 · Paraganglioma · n=10NCT05364944A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide FormulationTerminated · Phase 1 · Acromegaly · n=19NCT05050942A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NETActive Not Recruiting · Phase 3 · Gastro-enteropancreatic Neuroendocrine Tumor · n=332NCT06878664Randomized Interval Assessment Trial of Lu177-Dotatate Every 8 Versus Every 16 Weeks in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NETs) to Lower TOxicityRecruiting · Phase 3 · Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) · n=166NCT03289741A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine TumorsCompleted · Phase 4 · Neuroendocrine Tumors · n=51

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41712302Paul A, Mendis S et al. · Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada.Cancer control : journal of the Moffitt Cancer Center (2026)HumanPMID 38290866Bhat SZ, Salvatori R · Current role of pasireotide in the treatment of acromegaly.Best practice & research. Clinical endocrinology & metabolism (2024)HumanPMID 38847075Sood A, Munir M et al. · An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.Expert opinion on drug safety (2024)HumanPMID 39570708Bahri N, Crook C et al. · Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?Oncology (Williston Park, N.Y.) (2024)HumanPMID 37088017La Salvia A, Modica R et al. · Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists.Cancer treatment reviews (2023)HumanPMID 36294341Krawczyk S, Urbanska K et al. · Congenital Hyperinsulinaemic Hypoglycaemia-A Review and Case Presentation.Journal of clinical medicine (2023)PMID 36896924Varas Lorenzo M · Carcinoid syndrome and somatostatin analogues.Revista espanola de enfermedades digestivas (2023)HumanPMID 37434648George J, Ramage J et al. · The role of serotonin inhibition within the treatment of carcinoid syndrome.Endocrine oncology (Bristol, England) (2023)HumanPMID 35078191Allaw MB, Switchenko JM et al. · Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.Oncology (2022)HumanPMID 35587448Cuff H, Lord K et al. · The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.The Journal of clinical endocrinology and metabolism (2022)HumanPMID 32725444Bernabéu I, Fajardo C et al. · Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.Endocrine (2021)HumanPMID 33052555Caplin ME, Pavel M et al. · Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.Endocrine (2021)HumanPMID 33098539Akirov A, Masri-Iraqi H et al. · Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel.Endocrine (2021)HumanPMID 32440136Corica G, Ceraudo M et al. · Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management (2020)HumanPMID 30582380Godara A, Siddiqui NS et al. · The safety of lanreotide for neuroendocrine tumor.Expert opinion on drug safety (2019)HumanPMID 27822010Paragliola RM, Prete A et al. · Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors.Drug design, development and therapy (2017)HumanPMID 26917486Ruszniewski P, Valle JW et al. · Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2017)HumanPMID 27635672Ito T, Lee L et al. · Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Expert opinion on pharmacotherapy (2017)HumanPMID 26635177Saif MW · Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Expert opinion on pharmacotherapy (2016)HumanPMID 26126910Sun L, Yu CY et al. · Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.Current topics in medicinal chemistry (2016)Human

Showing 20 of 28 papers. View all on PubMed →